Primo Lara, MD
Enriched profileDirector, UC Davis Comprehensive Cancer Center; Executive Associate Dean for Cancer Programs; Distinguished Professor of Medicine · UC Davis School of Medicine; UC Davis Comprehensive Cancer Center
Primo Lara is Director, UC Davis Comprehensive Cancer Center; Executive Associate Dean for Cancer Programs; Distinguished Professor of Medicine at UC Davis School of Medicine; UC Davis Comprehensive Cancer Center. OpenAlex indexes 975 publications with 26,914 citations (h-index 77); ClinicalTrials.gov lists 24 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the FindMyKOL directory.
Data verified 18 Oct 2026
Overview
Updated 25 Oct 2026
Primo Lara, M.D., is Director, UC Davis Comprehensive Cancer Center at UC Davis School of Medicine; UC Davis Comprehensive Cancer Center. The public record shows 975 publications with 26,914 citations (h-index 77), centered on Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, Bladder and Urothelial Cancer Treatments. It also documents an investigator role on 24 registered clinical trials, industry payments reported by 6 companies, 6 NIH-funded awards (2003–2026).
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Prostate Cancer Treatment and Research
- 24 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 12 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 323.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 24 registered studies on ClinicalTrials.gov. The most recent:
- Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
Sponsor: University of California, Davis
- Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
Sponsor: University of California, Davis
Industry payments
Updated 25 Oct 2026
6 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Genmab U.S., Inc.Program year20242 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
63.8%Anti-androgens27.7%Nubeqa100%Part D<11 patientsCytochrome P450 17A1 Inhibitor12.8%Abiraterone Acetate100%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
22.9%Corticosteroid13.8%Prednisone100%Part D<11 patientsSerotonin-3 Receptor Antagonist9%Ondansetron Hcl100%Part D<11 patientsSensory organs
6.9%Corticosteroid6.9%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 25 Oct 2026
6 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- SWOG Network Group Operations Center of the NCTN
University of California at Davis
FY2026$10,929,371U10CA180888 - SWOG Network Group Operations Center of the NCTN
University of California at Davis
FY2026$4,439,060U10CA180888 - SWOG Network Group Operations Center of the NCTN
University of California at Davis
FY2026$4,225,017U10CA180888
Congress activity
Updated 25 Oct 2026
264 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 3678: Capturing Latino health disparities: Lessons from mail and community-based population health surveys in California
AACR Annual Meeting
AACR2026Co-author - A pragmatic phase 2 trial of locally ablative therapy in oligo-progressive genitourinary (GU) tumors: LAYOVER
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 25 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer.
Nanomedicine (London, England)
Article2026 - Capturing Latino Health Disparities: Lessons from Mail- and Community-Based Population Health Surveys in California.
Cancer research communications
Article2026 - Cancer statistics, 2026: Charting a course for a national cancer research agenda.
CA: a cancer journal for clinicians
Editorial2026 - The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404).
Cancer research communications
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Genomic Hallmarks and Structural Variation in Metastatic Prostate CancerArticle732 citations2018
- 04Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyArticle671 citations2022
- 05
Network
Updated 25 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/primo-lara-md
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
health.ucdavis.edu/medical-school/leadership/bios/primo-lara
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →swog.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- Editorial Board Member
Journal of Clinical Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Chair
Continuing Medical Education Subcommittee; Genitourinary Cancers Track Leader, American Society of Clinical Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Co-Chair
Investigational Drug Steering Committee, National Cancer Institute
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →health.ucdavis.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)